<DOC>
	<DOCNO>NCT01948791</DOCNO>
	<brief_summary>To investigate efficacy Exelon capsule maximal tolerate dose mild moderate Chinese AD patient via dosage titration 3mg/d 12mg/d 16 week duration</brief_summary>
	<brief_title>16w Interventional Study Titration Dose/Efficacy Assessment Exelon Chinese Alzheimer 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Key Have diagnosis dementia Alzheimer 's type accord DSMIV criterion clinical diagnosis probable AD accord NINCDS/ADRDA criterion MMSE score ≥ 10 ≤ 26 The treatment naïve patient one stop donepezil , galantamine , huperzine A , memantine least 2 week Be stable medical condition Have sign inform consent form patient his/her legal guardian Key Severe AD Patients history cerebrovascular disease , Active uncontrolled epilepsy , Active hypothyroidism , asthma , CNS infection , Neurodegenerative disorder , advance , severe , progressive , unstable medical condition Attending clinical trial take clinical trial drug A score &gt; 4 Modified Hachinski Ischemic Scale ( MHIS ) ; Patients use AChEI memantine</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>ENA713</keyword>
	<keyword>Chinese patient</keyword>
	<keyword>INSTINCT</keyword>
</DOC>